痤瘡治療市場 - 全球產業規模、佔有率、趨勢、機會和預測（按治療分類、配方、類型、痤瘡類型、分銷管道、地區和競爭格局分類），2021-2031年

全球痤瘡治療市場預計將從2025年的118.7億美元成長到2031年的166.3億美元，複合年成長率（CAGR）為5.78%。該市場涵蓋多種治療方法和程序，包括全身性抗生素、外用類視色素和荷爾蒙療法，旨在調節皮脂分泌、抑制細菌生長和減輕發炎。推動市場成長的關鍵因素是成人和青少年尋常性痤瘡發病率的上升，以及全球對外觀和護膚的日益關注。此外，青春痘常常會對患者的自尊心和生活品質產生負面影響，造成沉重的心理負擔，促使人們尋求專業的皮膚科治療，並持續推動對有效治療方案的需求。

根據美國皮膚病學會的數據，痤瘡將在2025年繼續成為美國最常見的皮膚病，每年影響多達5,000萬美國。如此高的發生率使得穩定的治療藥物供應至關重要。然而，市場面臨著與藥物治療長期安全性相關的重大挑戰，尤其是顯著增加的皮膚不良反應風險和抗生素抗藥性。這些安全隱患可能導致患者和醫生猶豫不決，限制標準藥物療法的普及，並阻礙整個行業的擴張。

市場促進因素

消費者對美容和皮膚健康的日益關注是推動市場擴張的主要動力，從根本上改變了皮膚科護理的方式。隨著社群媒體和數位平台的普及，人們對皮膚外觀的關注度不斷提高，患者越來越傾向於選擇專業治療而非暫時性的美容方案，這促使市場對經臨床檢驗、能夠彌合化妝品和藥品之間差距的產品需求激增。這一趨勢正推動著行業主要參與者的快速成長。例如，根據歐萊雅於2024年2月發布的2023年度報告，該公司皮膚科美容部門的銷售額年增28.4%，這一增速遠超整體美容市場。這凸顯了健康意識消費在推動實證痤瘡治療方案廣泛應用方面發揮的重要作用。

同時，新型全身和局部藥物療法的推出正在重塑競爭格局，這些療法解決了傳統抗生素相關的安全問題和未滿足的醫療需求。製藥公司正成功應用創新作用機制，例如雄性激素受體抑制劑，這類藥物針對痤瘡的荷爾蒙根源，同時最大限度地降低系統性抗藥性的風險。近期的數據反映了這些先進治療方法的快速普及。 Cosmo Pharmaceuticals 在其 2025 年 1 月發布的「2024 會計年度初步審核業績」中報告稱，Winlevi 已成為美國銷量最高的品牌局部痤瘡治療藥物，處方箋超過 120 萬張。同時，Galderma 在 2024 年 2 月的報告中指出，在治療性皮膚病學領域強勁成長的推動下，其年度淨銷售額達到創紀錄的 40.82 億美元。

市場挑戰

長期藥物治療帶來的安全隱患，尤其是皮膚不良反應和抗生素抗藥性風險的增加，對全球痤瘡治療市場構成了重大障礙。隨著醫學界對長期使用抗生素風險的認知不斷加深，處方醫師在使用傳統高劑量療法時也變得越來越謹慎。這種臨床上的謹慎態度導致處方量減少、療程縮短，直接限制了現有全身性藥物的收入；同時，患者對微生物群紊亂等副作用的擔憂進一步降低了用藥依從性，並減緩了市場成長。

儘管存在這些擔憂，但人們對這些藥物的依賴程度仍然很高，凸顯了該行業面臨的巨大挑戰。根據美國疾病管制與預防中心（CDC）的數據顯示，到2024年，皮膚科醫師開立的口服抗生素處方量將達到約510萬個療程，在所有醫學專科中仍將維持最高的處方率。如此高的處方量給皮膚科領域帶來了巨大壓力，迫使其透過醫療管理計畫大幅降低抗生素的使用量，而隨著標準治療通訊協定逐漸減少對這些主要藥物的依賴以降低安全風險，市場成長也因此受到限制。

市場趨勢

親水膠體祛痘貼的日益普及正在從根本上改變消費行為，它認可了可見的治療方法，並為傳統的局部用藥提供了一種非侵入性的替代方案。與通常隱蔽使用的乳霜不同，這些粘貼式祛痘貼被作為生活方式配件進行銷售，既能減少與痘痘相關的社會恥辱感，又能保護皮膚屏障免受接觸和外部刺激。這種向便捷一次性包裝的轉變正在為大型個人護理集團帶來顯著的商業性成長動力。例如，Church & Dwight 於 2024 年 11 月發布的「2024 會計年度第三季業績報告」指出，其國內消費者淨銷售額的成長主要得益於 HERO 祛痘產品的出色表現，凸顯了該品類在其整體產品組合收入中的重要作用。

同時，面向消費者的遠距皮膚科服務的擴展正在克服與門診就診相關的後勤障礙，使更多人能夠獲得處方箋級別的治療。利用非同步諮詢，數位健康平台將患者與認證的醫療保健提供者連接起來，從而能夠大規模地提供個人化配方的處方藥，這些藥物比標準非處方藥更能精準地滿足個體皮膚需求。這種模式有效地解決了皮膚科醫療服務取得的不平等問題，並正在發展成為一種高度擴充性的收入來源。例如，Hims & Hers Health 在 2024 年 11 月發布的「2024 年第三季財務業績」中報告稱，其收入為 4.016 億美元，同比成長 77%，這主要得益於其個性化皮膚科和健康服務的積極擴張。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球痤瘡治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 治療類型（類視色素、抗生素、荷爾蒙、抗發炎藥物、化學換膚、其他）
  • 依劑型（外用、口服、注射）
  • 依類型（處方藥、非處方藥）
  • 痤瘡類型（囊腫型痤瘡、術後/傷口痤瘡、粉刺型痤瘡、發炎性痤瘡）
  • 按分銷管道（醫院、零售店、藥局/藥局、電子商務）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美痤瘡治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲痤瘡治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章 亞太地區痤瘡治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章 中東和非洲痤瘡治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲痤瘡治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球痤瘡治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Johnson & Johnson Services, Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Sanofi SA
• L'Oreal SA
• Procter & Gamble Co.
• Teva Pharmaceutical Industries Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Acne Treatment Market is projected to expand from USD 11.87 Billion in 2025 to USD 16.63 Billion by 2031, registering a CAGR of 5.78%. This market encompasses a wide range of therapeutic agents and procedures, such as systemic antibiotics, topical retinoids, and hormonal therapies, which function by regulating sebum production, inhibiting bacterial growth, and reducing inflammation. Growth is primarily propelled by the rising incidence of acne vulgaris among both adults and adolescents, alongside a global prioritization of physical appearance and skincare. Additionally, the severe psychological toll of the condition, which frequently negatively impacts self-esteem and quality of life, drives individuals to pursue professional dermatological treatment, thereby maintaining demand for effective management solutions.

According to data from the American Academy of Dermatology, in 2025, acne remains the most prevalent skin condition in the United States, impacting up to 50 million Americans annually. This high prevalence highlights the critical need for consistent therapeutic availability. However, the market faces significant hurdles related to the safety profiles of long-term pharmaceutical interventions, specifically the escalating risks of adverse cutaneous reactions and antibiotic resistance. These safety concerns generate hesitation among both patients and prescribers, which potentially restricts the widespread adoption of standard pharmacological regimens and hinders the overall expansion of the sector.

Market Driver

The growing consumer focus on aesthetics and skin health serves as a major driver for market expansion, fundamentally altering the approach to dermatological care. As social media and digital platforms amplify awareness regarding skin appearance, patients are increasingly favoring professional interventions over temporary cosmetic solutions, triggering a surge in demand for clinically validated products that bridge the gap between cosmetics and pharmaceuticals. This trend has fueled rapid growth for major industry players; for instance, L'Oreal's 'Annual Report 2023', released in February 2024, revealed that its Dermatological Beauty Division achieved an impressive like-for-like sales increase of +28.4%, significantly outpacing the general beauty market and highlighting the importance of health-conscious spending in driving the adoption of science-backed acne solutions.

Concurrently, the competitive landscape is being reshaped by the introduction of novel systemic and topical pharmacotherapies that address safety concerns and unmet medical needs linked to traditional antibiotics. Pharmaceutical companies are successfully launching innovative mechanisms, such as androgen receptor inhibitors, that target the hormonal origins of acne while minimizing systemic resistance risks. The rapid uptake of these advanced treatments is reflected in recent data; Cosmo Pharmaceuticals reported in their January 2025 'Preliminary Unaudited 2024 Results' that Winlevi has become the leading branded topical acne treatment in the U.S. with over 1.2 million prescriptions, while Galderma's February 2024 report cited record full-year net sales of 4.082 billion USD, driven by momentum in therapeutic dermatology.

Market Challenge

The safety concerns surrounding long-term pharmaceutical interventions, particularly regarding adverse cutaneous reactions and the growing risk of antibiotic resistance, constitute a major obstacle for the Global Acne Treatment Market. As the medical community becomes more aware of the dangers linked to prolonged antibiotic exposure, prescribers are increasingly hesitant to utilize these traditional high-volume regimens. This clinical caution results in reduced prescription volumes and shorter treatment durations, directly limiting revenue for established systemic agents, while patient anxiety regarding side effects like microbiome disruption further lowers adherence rates and dampens market performance.

Despite these concerns, reliance on these pharmaceuticals remains high, underscoring the magnitude of the industry's challenge. According to the Centers for Disease Control and Prevention, dermatologists prescribed approximately 5.1 million courses of oral antibiotics in 2024, maintaining the highest prescription rate among medical specialists. This heavy prescription volume subjects the dermatology sector to intense pressure from health stewardship programs to significantly curtail usage, consequently restricting market growth as standard-of-care protocols evolve away from these pharmaceutical mainstays to mitigate safety risks.

Market Trends

The rising popularity of hydrocolloid acne patches is fundamentally transforming consumer behavior by validating visible treatment methods and providing a non-invasive alternative to traditional topical applications. Unlike creams that are typically applied discreetly, these adhesive solutions are marketed as lifestyle accessories, which helps reduce the stigma surrounding breakouts while physically shielding the skin barrier from picking and external irritants. This transition toward convenient, single-use formats has created significant commercial momentum for major personal care conglomerates; for example, Church & Dwight's 'Q3 2024 Results' in November 2024 noted that domestic consumer net sales growth was largely driven by the performance of HERO acne products, emphasizing the category's vital role in broader portfolio revenue.

Simultaneously, the expansion of direct-to-consumer teledermatology services is democratizing access to prescription-strength management by overcoming the logistical hurdles of in-office appointments. Digital health platforms utilize asynchronous consultations to link patients with licensed providers, facilitating the scalable delivery of personalized compounded formulations that treat individual skin needs more accurately than standard over-the-counter options. This model effectively bridges the gap in dermatological accessibility and has become a highly scalable revenue source; as evidence, Hims & Hers Health reported in their November 2024 'Third Quarter 2024 Financial Results' a 77% year-over-year revenue surge to $401.6 million, fueled by the aggressive scaling of their personalized dermatology and health offerings.

Key Market Players

• Johnson & Johnson Services, Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Sanofi S.A.
• L'Oreal S.A.
• Procter & Gamble Co.
• Teva Pharmaceutical Industries Ltd.

Report Scope

In this report, the Global Acne Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acne Treatment Market, By Therapeutic Class

• Retinoids
• Antibiotics
• Hormonal Drugs
• Anti-Inflammatory Drugs
• Chemical Peels
• Others

Acne Treatment Market, By Formulation

• Topical Medications
• Oral Medications
• Injectables

Acne Treatment Market, By Type

• Prescription Medicines
• Over-The-Counter Medicines

Acne Treatment Market, By Acne Type

• Cystic Acne
• Postsurgical/Wound Acne
• Comedonal Acne
• Inflammatory Acne

Acne Treatment Market, By Distribution Channel

• Hospitals
• Retail Stores
• Pharmacies & Drug Stores
• E-Commerce

Acne Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acne Treatment Market.

Available Customizations:

Global Acne Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acne Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutic Class (Retinoids, Antibiotics, Hormonal Drugs, Anti-Inflammatory Drugs, Chemical Peels, Others)
  • 5.2.2. By Formulation (Topical Medications, Oral Medications, Injectables)
  • 5.2.3. By Type (Prescription Medicines, Over-The-Counter Medicines)
  • 5.2.4. By Acne Type (Cystic Acne, Postsurgical/Wound Acne, Comedonal Acne, Inflammatory Acne)
  • 5.2.5. By Distribution Channel (Hospitals, Retail Stores, Pharmacies & Drug Stores, E-Commerce)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Acne Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutic Class
  • 6.2.2. By Formulation
  • 6.2.3. By Type
  • 6.2.4. By Acne Type
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Acne Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutic Class
      • 6.3.1.2.2. By Formulation
      • 6.3.1.2.3. By Type
      • 6.3.1.2.4. By Acne Type
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Acne Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutic Class
      • 6.3.2.2.2. By Formulation
      • 6.3.2.2.3. By Type
      • 6.3.2.2.4. By Acne Type
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Acne Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutic Class
      • 6.3.3.2.2. By Formulation
      • 6.3.3.2.3. By Type
      • 6.3.3.2.4. By Acne Type
      • 6.3.3.2.5. By Distribution Channel

7. Europe Acne Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutic Class
  • 7.2.2. By Formulation
  • 7.2.3. By Type
  • 7.2.4. By Acne Type
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Acne Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutic Class
      • 7.3.1.2.2. By Formulation
      • 7.3.1.2.3. By Type
      • 7.3.1.2.4. By Acne Type
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. France Acne Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutic Class
      • 7.3.2.2.2. By Formulation
      • 7.3.2.2.3. By Type
      • 7.3.2.2.4. By Acne Type
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. United Kingdom Acne Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutic Class
      • 7.3.3.2.2. By Formulation
      • 7.3.3.2.3. By Type
      • 7.3.3.2.4. By Acne Type
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. Italy Acne Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutic Class
      • 7.3.4.2.2. By Formulation
      • 7.3.4.2.3. By Type
      • 7.3.4.2.4. By Acne Type
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Acne Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutic Class
      • 7.3.5.2.2. By Formulation
      • 7.3.5.2.3. By Type
      • 7.3.5.2.4. By Acne Type
      • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Acne Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutic Class
  • 8.2.2. By Formulation
  • 8.2.3. By Type
  • 8.2.4. By Acne Type
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Acne Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutic Class
      • 8.3.1.2.2. By Formulation
      • 8.3.1.2.3. By Type
      • 8.3.1.2.4. By Acne Type
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Acne Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutic Class
      • 8.3.2.2.2. By Formulation
      • 8.3.2.2.3. By Type
      • 8.3.2.2.4. By Acne Type
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Acne Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutic Class
      • 8.3.3.2.2. By Formulation
      • 8.3.3.2.3. By Type
      • 8.3.3.2.4. By Acne Type
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Acne Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutic Class
      • 8.3.4.2.2. By Formulation
      • 8.3.4.2.3. By Type
      • 8.3.4.2.4. By Acne Type
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Acne Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutic Class
      • 8.3.5.2.2. By Formulation
      • 8.3.5.2.3. By Type
      • 8.3.5.2.4. By Acne Type
      • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Acne Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutic Class
  • 9.2.2. By Formulation
  • 9.2.3. By Type
  • 9.2.4. By Acne Type
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Acne Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutic Class
      • 9.3.1.2.2. By Formulation
      • 9.3.1.2.3. By Type
      • 9.3.1.2.4. By Acne Type
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. UAE Acne Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutic Class
      • 9.3.2.2.2. By Formulation
      • 9.3.2.2.3. By Type
      • 9.3.2.2.4. By Acne Type
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. South Africa Acne Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutic Class
      • 9.3.3.2.2. By Formulation
      • 9.3.3.2.3. By Type
      • 9.3.3.2.4. By Acne Type
      • 9.3.3.2.5. By Distribution Channel

10. South America Acne Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutic Class
  • 10.2.2. By Formulation
  • 10.2.3. By Type
  • 10.2.4. By Acne Type
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Acne Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutic Class
      • 10.3.1.2.2. By Formulation
      • 10.3.1.2.3. By Type
      • 10.3.1.2.4. By Acne Type
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Colombia Acne Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutic Class
      • 10.3.2.2.2. By Formulation
      • 10.3.2.2.3. By Type
      • 10.3.2.2.4. By Acne Type
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. Argentina Acne Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutic Class
      • 10.3.3.2.2. By Formulation
      • 10.3.3.2.3. By Type
      • 10.3.3.2.4. By Acne Type
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Acne Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Johnson & Johnson Services, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GlaxoSmithKline plc
• 15.3. Pfizer Inc.
• 15.4. Novartis AG
• 15.5. Bayer AG
• 15.6. Eli Lilly and Company
• 15.7. Sanofi S.A.
• 15.8. L'Oreal S.A.
• 15.9. Procter & Gamble Co.
• 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer